CAS 123955-10-2: Almokalant

Almokalant: Class III antiarrhythmic, K+ channel blocker, inhibits Ikr current.

Almokalant is an investigational antiarrhythmic drug, which is a synthetic pharmaceutical compound. It is derived from the class of drugs known as selective potassium channel blockers. Almokalant's mode of action involves the blockade of hERG (human Ether-à-go-go-Related Gene) potassium channels. This blockade prolongs the cardiac action potential duration, which can be beneficial in stabilizing irregular heartbeats. The primary application of Almokalant is in the treatment of cardiac arrhythmias, specifically targeting conditions characterized by abnormal heart rhythms. Its ability to modify cardiac electrical activity makes it a candidate for controlling arrhythmias and potentially preventing arrhythmia-associated complications. However, it is crucial for ongoing research to evaluate its safety profile and therapeutic efficacy before clinical use can be widely recommended. Studies regarding its pharmacodynamics and pharmacokinetics are essential for a comprehensive understanding of its role in cardiac therapy.